|
|
| Countries covered: China With a rapidly growing economy, cost advantages, a skilled workforce, and a governmental commitment to the sciences, China is becoming increasingly important in the global biotechnology industry. Successful forays into high technology manufacturing and the increasing prestige of its scientific institutes have provided China with a strong platform for high-tech development. China Antibodies is an essential resource for companies, investors and entrepreneurs interested in accessing China’s antibody industry. This report offers a comprehensive overview and analysis of China’s antibody industry together with a directory of more than 30 antibody-related enterprises. Detailed case studies and profiles of companies are included with information such as company size, customer segments, and executive profiles. This report includes cost data and addresses large-scale manufacturing. Database of China Antibodies included: China Antibodies database includes 30+ Chinese antibody companies that produce antibody products or provide antibody services. Antibody products include antibodies for laboratory use, diagnostic use, and therapeutic antibodies. Antibody services refer to the tailored antibody preparation services including monoclonal and polyclonal antibody preparation. All of the antibody companies in the database include the following information: I. Contact information II. Company general information III. Details on products and services provided |
More China Antibody Technologies Reports
Research Report on Chinese Monoclonal Antibody Industry, 2012 by
China Research and Intelligence Co., Ltd.
Antibody medicine is generally obtained from monoclonal antibody through genetic engineering, possessing the advantages of strong targeting and few drug side effects. At the present ...
China Monoclonal Antibody Industry Report, 2010-2011 by
Research in China
China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries ...
Chinese Markets for Monoclonal Antibody by
Asia Market Information & Development Company
China's demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will ...
Analysis Report on China's Antineoplastic Market by
SunFAITH China Ltd.
The industrialized process causes the aggravation of environmental pollution, the growth of people's life expectancy, making the incidence of tumor higher. Because multi-links on the ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Juice – China – a snapshot (2010) by
Mintel - Snapshots
Juice in China by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. The report covers packaged ...
See all reports like this >>
Related Markets
Antibody Technologies Reports
- Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides
- Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
